Achillion Pharma (ACHN) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-57.28M
Depreciation and amortization	690K
Noncash stock based compensation	8.3M
Noncash interest expense
(Gain) loss on disposal of equipment	8K
Amortization of premium on marketable securities	924K
Accounts receivable
Prepaid expenses and other assets	-15K
Accounts payable	1.1M
Accrued expenses	-2.35M
Net cash used in operating activities
Purchases of fixed assets	-1.77M
Purchases of marketable securities	-404.03M
Maturities of marketable securities
Net cash provided by (used in) by investing activities
Proceeds from sale of common stock, net of issuance costs
Proceeds from exercise of stock options	71K
Proceeds from sale of common stock under Employee Stock Purchase Plan	126K
Payment of deferred financing costs
Borrowings of debt	0
Repayments of debt
Net cash provided by financing activities
Net increase in cash and cash equivalents	-41.36M
Cash and cash equivalents, beginning of period	81.73M
Cash and cash equivalents, end of period	40.36M
Cash paid for interest	33K

Entities mentioned with ACHN

View All Entities